Stock Price Movement and Senior Notes Redemption - Research Report on Valeant, Edwards Lifesciences, Alkermes, Mallinckrodt, and

Stock Price Movement and Senior Notes Redemption - Research Report on Valeant,
        Edwards Lifesciences, Alkermes, Mallinckrodt, and Dr. Reddy's

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 6, 2013

NEW YORK, December 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant
Pharmaceuticals Intl Inc. (NYSE: VRX), Edwards Lifesciences Corp (NYSE: EW),
Alkermes Plc (NASDAQ: ALKS), Mallinckrodt PLC (NYSE: MNK), and Dr. Reddy's
Laboratories Limited (ADR) (NYSE: RDY). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Valeant Pharmaceuticals Intl Inc. Research Report 

On December 2, 2013, Valeant Pharmaceuticals International, a wholly-owned
subsidiary of Valeant Pharmaceuticals International, Inc., announced the
redemption of its remaining $465.5 million aggregate principal amount of its
outstanding 6.50% Senior Notes due 2016 (CUSIP Nos. 91911XAR5, U9098VAH5) (the
Notes). According to the Company, on November 15, 2013, Valeant
Pharmaceuticals International mailed an irrevocable notice of redemption for
$450 million aggregate principal amount of the Notes. Additionally, the
Company informed that on December 2, 2013, The Bank of New York Mellon Trust
Company has mailed a copy of the irrevocable notice of redemption with respect
to the remaining Notes to record holders of the Notes, as trustee under the
indenture governing the Notes. The Full Research Report on Valeant
Pharmaceuticals Intl Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9fdd_VRX

--

Edwards Lifesciences Corp Research Report

On December 3, 2013, shares of Edwards Lifesciences Corp (Edwards
Lifesciences) fell 0.52% to $65.13 at the end of trading session. Edwards
Lifesciences' stock declined 0.26% over the past three trading sessions, as
compared to the Dow Jones Industrial Average Index which declined by 1.14%
during the same period. The Full Research Report on Edwards Lifesciences Corp
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/48b8_EW

--

Alkermes Plc Research Report

On December 3, 2013, Alkermes Plc's (Alkermes) stock rose 0.15% to end trading
session at $41.12. Over the previous three trading sessions, Alkermes' shares
gained 3.32% compared to the Nasdaq composite Index which declined 0.19%
during the same period. The Full Research Report on Alkermes Plc - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/e2f3_ALKS

--

Mallinckrodt PLC Research Report

On December 3, 2013, shares of Mallinckrodt PLC (Mallinckrodt) ended the
trading session at $51.54, down by 1.47%. Over the previous three trading
sessions, Mallinckrodt's stock declined 0.50% as compared to the Dow Jones
Industrial Average Index which dropped 1.14% during the same period. The Full
Research Report on Mallinckrodt PLC - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/24f6_MNK

--

Dr. Reddy's Laboratories Limited (ADR) Research Report

On December 3, 2013, Dr. Reddy's Laboratories Limited (ADR)'s (Dr. Reddy's)
stock dropped 1.25% to end trading session at $39.54. Dr. Reddy's stock rose
0.30% over the past three trading sessions, while the Dow Jones Industrial
Average Index dropped 1.14% in the same period. The Full Research Report on
Dr. Reddy's Laboratories Limited (ADR) - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/ea85_RDY

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.